Zulassungsverfahren für neue Arzneimittel in Europa
Author:
Publisher
Springer Berlin Heidelberg
Link
http://link.springer.com/content/pdf/10.1007/978-3-662-57386-0_2
Reference119 articles.
1. Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale T (2015): Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? Pharmacoepidemiol and Drug Saf 24:709–715
2. Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne I-M, Spooner A, Rain J, Rasi G (2014): Proactively managing the risk of marketed drugs: experience with the EMA pharmacovigilance risk assessment committee. Nat Rev Drug Discovery 13: 395–397
3. Arnadottir AH, Haajer-Ruskamp FM, Straus SMJ, Eichler HG, de Graeff PA, Mol PGM (2011): Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 72: 490–499
4. Avorn J, Kesselheim AS (2015): The 21st century cures act – Will it take us back in time? N Engl J Med 372: 2473–2475
5. Baird LG, Banken R, Eichler HG, Kristensen FB, Lee DK, Lim JC, Lim R, Longson C, Pezalla E, Salmonson T, Samaha D, Tunis S, Woodcock J, Hirsch G (2014): Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther 96: 559–571
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Orphan Drugs aus Sicht der Arzneimittelkommission der deutschen Ärzteschaft;Der Internist;2019-03-11
2. Orphan-Arzneimittel;Arzneiverordnungs-Report 2019;2019
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3